New data about Pfizer COVID-19 efficacy after the first dose suggests high efficacy, raising questions about potential alternative dosing schedules.
The Oxford-AstraZeneca COVID-19 vaccine, ChAdOx1, released 4 studies to analyze its efficacy in the prevention of mild, moderate, and severe COVID-19 infection; new studies also address rising concerns in the vaccine’s ability to protect against variants B.1.1.7 and B.1.351.
We speak with Mildred Solomon, EdD, President of the Hastings Center and Professor of Global Health and Social Medicine at Harvard Medical School, where she directs the school’s Fellowship in Bioethics, about the COVID-19 pandemic, health equity, and vaccine distribution.
Moderna and Pfizer provide updates on mRNA vaccines against variant B.1.1.7; Infectious Diseases Society of America holds media briefing on COVID-19 variants.